Protagen closes financing for UNIarray

German firm Protagen AG, a provider of protein analytical services, bio-informatics and biochips, has closed a new round of financing.

The capital raised in this round has come from the existing institutional investors, MIG AG, Munich, S-Venture Capital Dortmund GmbH and Kreditanstalt fur Wiederaufbau, and will be used to strengthen and expand the company's UNIarray technology position and the development of novel diagnostics.

UNIarray is a unique technology platform for the development of novel diagnostics based on indication-specific auto antibody patterns in patient serums. In addition, UNIarray serves as a platform for the development of product-specific companion diagnostics and patient stratification for clinical studies. In-house research at Protagen is presently focused on novel diagnostics for prostate cancer, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, Morbus Parkinson and Alzheimer's disease.